Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection – Yahoo Finance

SER-109 satisfied Phase 3 main endpoint, showing a highly statistically significant 30.2% absolute decrease in the rate of C. difficile infection reoccurrence compared to placebo Efficacy results substan … [+15608 chars]